The prevalence of painful diabetic peripheral neuropathy (DPN) was evaluated in type 1 or type 2 diabetes mellitus patients (n = 4097) attending outpatient clinics across the Middle East. Overall, 53.7% of 3989 patients with DN4 data met the criteria for painful DPN (Douleur Neuropathique-4 [DN4] scores ≥ 4). Significant predictors of painful DPN included long history (≥ 10 years) of diabetes (odds ratio [OR] 2.43), age ≥ 65 years (OR 2.13), age 50 -64 years (OR 1.75), presence of type 1 versus type 2 diabetes (OR 1.59), body mass index ≥ 30 kg/m 2 (OR 1.35) and female gender (OR 1.27). Living in one of the Gulf States was associated with the lowest odds of having painful DPN (OR 0.44). The odds of painful DPN were highest among patients with peripheral vascular disease (OR 4.98), diabetic retinopathy (OR 3.90) and diabetic nephropathy (OR 3.23). Because of the high prevalence and associated suffering, disability and economic burden of painful DPN, it is important that diabetic patients are periodically screened, using a simple instrument such as the DN4, and receive appropriate treatment if symptoms develop.
Introduction
A recent meta-analysis of 26 studies reported that the prevalence of diabetes mellitus in the Middle East Region (MER) was 10.5% (95% confidence interval [CI] 8.6, 12.7%). 1 The incidence of diabetes was found to have increased over the previous decade and was correlated with the presence of obesity (r 2 = 0.6; P = 0.01). 1 Diabetes is the most common cause of peripheral polyneuropathy; 25 -50% of diabetic patients in developed countries have peripheral polyneuropathy. 2, 3 Studies conducted in the MER report higher rates of S Jambart, Z Ammache, F Haddad et al. Painful diabetic peripheral neuropathy in the Middle East painful diabetic peripheral neuropathy (DPN), ranging from 35% to 65%. 4 -10 DPN accounts for more hospital admissions than all other diabetic complications combined and is responsible for 50 -75% of nontraumatic amputations. 11 It is estimated that approximately 15 -25% of cases of DPN are associated with neuropathic pain, 2, 3, 12, 13 which is defined as 'pain arising as a direct consequence of a lesion or disease affecting the somatosensory system'. 14 Few studies have specifically examined the prevalence of painful DPN and the reliability of these prevalence estimates is uncertain because most studies obtained data from questionnaires and did not include physical examinations. 3 Painful DPN is associated with a high degree of functional impairment, impairment in health-related quality of life and activities of daily living. 15 -18 Painful DPN reportedly results in significantly higher healthcare costs when compared with ageand sex-matched diabetic patients without DPN. 19 Annual healthcare costs in two separate databases were 24 -38% higher even after adjusting for differences in comorbid medical conditions such as cardiovascular illness. 19 For both type 1 and type 2 diabetes, the risk of developing distal polyneuropathiesincluding painful neuropathies -appears to be inversely related to the degree of glycaemic control and is directly correlated with the duration of diabetes. 2,20 -23 Higher body mass index (BMI) and smoking have been independently associated with the development of polyneuropathies. 23 The precise mechanisms involved in the pathogenesis of diabetic polyneuropathy are unclear, but appear to include mechanisms only indirectly related to hyperglycaemia. 24 -26 The main objective of the present study was to determine the prevalence of painful DPN among adults with type 1 or type 2 diabetes mellitus seeking treatment at outpatient clinics in the MER (specifically Egypt, Lebanon, Jordan and the Gulf States of Kuwait and the United Arab Emirates). A secondary objective of the study was to describe the clinical and demographic characteristics of subjects with and without painful DPN.
Patients and methods

STUDY DESIGN AND INCLUSION CRITERIA
This was a single-visit epidemiological study designed to measure the prevalence of painful DPN among patients with type 1 or type 2 diabetes in outpatient (primarily private sector) medical settings in the MER between January and December 2009. The study was non-interventional and did not involve administration of study drug or any other therapy. It was conducted in accordance with the legal and regulatory requirements of each country, as well as with good pharmacoepidemiology practice guidelines, 27 and was approved by appropriate Ethics Committees at each investigational site. All patients provided written informed consent.
Patients were included if they met all of the following criteria: aged ≥ 18 years; presenting at an outpatient clinic; current diagnosis of diabetes mellitus type 1 (duration ≥ 5 years) or type 2 (any duration); no current psychiatric (or any other) disorder that might affect the reliability of their response to the study questionnaire; no other type of neuropathic pain of non-diabetic origin (including but not limited to lower  back or neck pain [radiculopathy], postherpetic neuralgia, cancer related pain,  spinal-cord injury pain, multiple sclerosis  pain, carpal tunnel syndrome pain,  phantom pain, trigeminal neuralgia, or  general diffused pain [fibromyalgia] ).
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ASSESSMENTS
Study investigators completed a case-report form that anonymously recorded patients' demographic information (age, sex, race), clinical information (weight, height, BMI, smoking status [based on patient self reporting], medical history) and treatment history. The primary measure in the study was the Douleur Neuropathique-4 (DN4), which was used to identify the presence of painful DPN and is a brief 10-item questionnaire that is a valid screening test for painful neuropathic pain. 28 The first seven items of the DN4 rely on analysis of the patient's sensory description of their pain; the final three items are based on physical examination of sensory function. Patients with DN4 scores ≥ 4 have a 90% chance of having a diagnosis of neuropathic pain (painful DPN). In the original validation study, 17% of patients with scores of 2 or 3 also had a diagnosis of neuropathic pain (i.e. false-negative results). 29 Conversely, the diagnostic accuracy of the DN4 was shown to increase as the cut-off score increased from 4 to 5 (93%) or 6 (98.5%). An Arabic language version of the DN4 has been validated and has comparable sensitivity and specificity to the original. 10, 30 
STATISTICAL ANALYSES
Continuous variables were described using descriptive statistics such as mean ± SD and range. Patient counts and percentages were presented along with the 95% CI for categorical variables. Patients who presented a non-missing DN4 score ≥ 4 were considered positive for painful DPN. Comparison between the proportion of patients with painful DPN of pairwise categories within demographics, medical history data and concomitant medication were summarized using P-values of χ 2 tests, odds ratios (OR), and 95% CI for the OR. A multivariate regression analysis was performed using the presence of painful DPN (DN4 score ≥ 4) as the dependent variable. Independent variables included in the model were age, race, gender, BMI, smoking status, type of diabetes, duration since first diagnosis of diabetes and country. The stepwise method was used for the selection of independent variables.
Results
A total of 4097 patients were enrolled into the study from 400 private-practice clinics across the MER. Demographic and clinical data for the study sample are summarized in Table 1 . The majority of patients were white males, who ranged from 11 to 107 years of age. Most patients were either overweight or obese, with a mean ± SD BMI of 29.4 ± 5.1 kg/m 2 , 26.2% of the patients were current smokers and 16.4% were ex-smokers.
In the total population, 90.6% of the patients had type 2 diabetes (Table 1) . Patients reported a range of diabetic complications including diabetic nephropathy (794/4097; 19.4%), diabetic retinopathy (688/4097; 16.8%) and erectile dysfunction (719/4097; 17.5%). Patients also reported concurrent diagnoses of hypertension (2444/4097; 59.7%), dyslipidaemia, (2316/4097; 56.5%), peripheral vascular disease (549/4097; 13.4%), and a past history of myocardial infarction (351/4097; 8.6%) and stroke (203/4097; 5.0%).
Each country/region differed in terms of demographics and clinical characteristics ( Table 2) . Egypt had the highest percentage of female patients and a slightly higher proportion of people with type 1 diabetes ( Table 2 ). In contrast, the Gulf States had the highest proportions of male patients and Asian patients ( Table 2 ). The mean age of patients was highest in Lebanon ( Table 2) 
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Of the 4097 patients enrolled in the study, DN4 data were missing from 108 patients and these patients were excluded from further analysis. Among patients who had DN4 data, 53.7% (2144/3989; 95% CI 52.2, 55.3) had DN4 scores ≥ 4 and met the criteria for painful DPN. Burning and numbness were the most frequently reported symptoms on the DN4 questionnaire, followed by tingling and 'pins and needles' (Fig. 1 ). For ) had a score of 5 -10. There were notable regional differences in the proportion of patients with DN4 scores ≥ 4, with the highest proportion being in those from Egypt (61.3%; 95% CI 57.9, 64.7%) and the lowest proportion among those from the Gulf States (37.1%; 95% CI 33.3, 40.8%; Fig. 2 ). This does not appear to be solely due to lower rates on the self-report items of the DN4, since the proportion of patients who reported two of the examination items -pain on brushing (14.6% versus 23.4 -29.4%) and hypoesthesia to touch (29.3% versus 36.3 -43.7%) -was also lower in the Gulf States compared with other countries.
Univariate OR were calculated to evaluate which demographic and clinical variables might be significantly associated with the presence of painful DPN (Table 3 ) and to determine potential association between specific medical illnesses or common diabetic complications and the presence of painful DPN ( Table 4 ). The odds of painful DPN were 
Discussion
The current study was designed to evaluate the prevalence of painful DPN among patients with type 1 or type 2 diabetes attending outpatient clinics in the MER. In this setting, 53.7% of diabetic patients met the criteria for painful DPN (DN4 score ≥ 4), with the highest incidence in Egypt (61.3%), followed by Jordan (57.5%), Lebanon (53.9%) and the Gulf States (37.1%). This incidence is notably higher than that observed in studies conducted in Europe and the USA, which reported prevalence rates of 15 -25%. 2, 3, 12, 13, 31 Rates of painful DPN can vary widely, depending on the patient populations studied and the criteria used to define painful DPN. Higher rates are typically described in studies involving patients with longer duration of diabetes, and in patients with type 1 diabetes, though duration of illness was not typically controlled for in the latter cases. 31 The potential validity of the prevalence estimate for painful DPN in the present study is strengthened by the cross-national nature of the sample, which comprised > 4000 patients recruited from 400 clinics across the 10 Additional published studies on DPN in the MER have reported prevalences ranging from 35% to 55%. 4 -9 The most likely explanation for the higher prevalence of painful DPN in MER diabetes populations is that they differ from Western populations in key clinical features that constitute risk factors for painful DPN development. For example, poor glycaemic control has been reported to be a significant risk factor for diabetic neuropathy in general and, specifically, for painful DPN both in Western studies 2, 22 and in those conducted in the MER. 6, 7 Several studies have reported that diabetes-related knowledge is low and poor glycaemic control is common (exceeding 50%) among diabetics in the MER. 32 -35 Glycosylated haemoglobin (HbA 1c ) levels were not obtained in the present study so it was not possible, therefore, to evaluate this hypothesis directly.
There were some limitations to the present study. First, while the study sample was large, it was not a fully representative population sample. Rather, the sample was drawn from patients being evaluated in private-practice settings; generalizations to the total population of diabetic patients in the MER should, therefore, be undertaken with caution. A second limitation was the use of the DN4 instrument to establish the presence of painful DPN. A cut-off score ≥ 4 has a high degree of sensitivity and specificity for diagnosing painful DPN 28 and the Arabic language version has similar performance characteristics to the original. 30 In fact, a cutoff score of 3, instead of 4, has been recommended for the Arabic version. 30 A more stringent DN4 cut score of 5 in the present study would still have yielded a prevalence rate of 41.2% for painful DPN. 28 This latter, more conservative, prevalence estimate is still considerably higher than the 15 -25% prevalence estimates for painful DPN reported in Western populations. 2, 3, 12, 13, 31 The third limitation was the lack of HbA 1c measurement which would have provided a quantitative measure of the adequacy of diabetes control.
It should be noted that the Gulf States recorded a much higher proportion of Asian patients in the present study. This appears to be due to investigators in the Gulf States categorizing patients based on geography instead of ethnicity, since the Gulf States are technically part of the Asian land mass.
The multivariate regression analysis found that duration since first diagnosis of diabetes (≥ 10 years) and older age (≥ 65 years and 50 -64 years) were the strongest independent predictors of the presence of painful DPN. To a lesser extent the presence of type 1 diabetes, BMI ≥ 30 kg/m 2 and female gender were also significant predictors. Patients with two or more predictor variables (e.g. elderly males with BMI ≥ 30 kg/m 2 ) should be screened for the presence of painful DPN because of the high degree of impairment in functioning and quality of life in patients with painful DPN. 15 -18 In the present patient sample, 68.8% of patients who met the DN4 criteria for painful DPN were taking medication to control their pain. Assessment of the adequacy and effectiveness of the treatments for painful DPN that were being used by the patients in this population was beyond the scope of this investigation. Evidence-based treatment guidelines in Western countries 36 -38 and in the MER 39 consistently recommend pregabalin and gabapentin as first-line treatments for painful DPN, with duloxetine as a second-line treatment. The extent to S Jambart, Z Ammache, F Haddad et al.
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which non-recommended treatmentsincluding carbamazepine and NSAIDscontinue to be prescribed was notable in the present patient population.
In conclusion, the present study demonstrated a high rate of painful DPN among diabetic patients attending clinics in the MER. Because of the high prevalence and associated suffering, disability and economic burden of painful DPN, it is important that physicians consider periodic screening for patients with type 1 or type 2 diabetes using an easily administered instrument such as the DN4. At-risk patients with high chronicity of diabetes, evidence of peripheral vascular disease, history of hypertension and/or dyslipidaemia, erectile dysfunction and diabetic neuropathy and/or nephropathy should be monitored closely, and appropriate treatment should be provided if painful neuropathic symptoms develop. 39 
